Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.45 |
| ▸ | CDC25C | P30307 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15807642 | 0.92 | KCNH2 (0.47) | KCNH2TSHRSIGMAR1NR1D1CDC25C | |
| SCHEMBL23727717 | 0.88 | KCNH2 (0.49) | KCNH2TSHRNR1D1CDC25CGAA | |
| SCHEMBL23727742 | 0.86 | KCNH2 (0.46) | KCNH2TSHRSIGMAR1NR1D1CDC25C | |
| SCHEMBL3156438 | 0.86 | NR1D1 (0.52) | KCNH2NR1D1GAAALDH1A1LMNA | |
| SCHEMBL30408958 | 0.85 | SIGMAR1 (0.49) | TSHRSIGMAR1ALDH1A1LMNAMAPT | |
| SCHEMBL3534499 | 0.85 | KCNH2 (0.53) | KCNH2TSHRSIGMAR1CDC25CGAA | |
| SCHEMBL16682344 | 0.84 | KCNH2 (0.53) | KCNH2TSHRNR1D1CDC25CKMT2A | |
| SCHEMBL19491362 | 0.83 | KCNH2 (0.52) | KCNH2TSHRSIGMAR1NR1D1CDC25C | |
| SCHEMBL1287149 | 0.83 | KCNH2 (0.46) | KCNH2TSHRSIGMAR1NR1D1CDC25C | |
| SCHEMBL31606972 | 0.83 | MAPT (0.52) | TSHRSIGMAR1NR1D1GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131016-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-4426714-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | Adcentrx Therapeutics Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2011140009-A1 | METHODS OF USING SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2373694-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BioMarin Pharmaceutical Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2010065174-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| US-6395905-B1 | GABA-A ALPHA 5 LIGANDS USEFUL FOR ENHANCING COGNITION: | MERCK SHARP & DOHME LTD. (GB) | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | KCNH2 4380/4885TSHR 3503/4885SIGMAR1 4728/4885 |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | KCNH2 1447/4885TSHR 3724/4885SIGMAR1 3623/4885 |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | ABL1, PRKCA, PRKCQ | KCNH2 620/4885TSHR 3140/4885SIGMAR1 4023/4885 |
| US-20260131016-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | FCGR2A, FCGR3B, AURKC | KCNH2 4141/4885TSHR 142/4885SIGMAR1 2547/4885 |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | SI, FUT6, B3GAT3 | KCNH2 979/4885TSHR 3307/4885SIGMAR1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.